Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- JPMA to Disclose More Information on Clinical Studies
October 5, 2009
- Kenporen Records Second-Largest Deficit in FY2008
October 5, 2009
- JPMA Studies How to Support Bioventures
October 5, 2009
- BSP Aims at Growing Twice as Fast as Market in Japan
October 5, 2009
- R&D NEWS IN BRIEF
October 5, 2009
- Eisai, Pfizer to Continue Copromotion of Aricept
October 5, 2009
- Nihon Chouzai, Matsumotokiyoshi Give Up Business Alliance
October 5, 2009
- Quintiles to Start COPD Management Services
October 5, 2009
- Hoyu Acquires 4 Kracie Group Companies
October 5, 2009
- DSP Starts Shipping New Amlodin OD Tab Produced Using SUITAB-NEX Technology
October 5, 2009
- Patient Recognition Criteria Approved for 11 Designated Diseases
October 5, 2009
- NEW PRODUCTS
October 5, 2009
- Mirtazapine Shows Fast, Long-Lasting Effects: Prof. Kinoshita
October 5, 2009
- Team Nagatsuma Sets Out
October 5, 2009
- TOPICS／Dr Karasawa Intends to Lead JMA for Another Term of Office
October 5, 2009
- Discussions on NHI Drug Pricing System Reform Remain Halted at Chuikyo
October 5, 2009
- PMS Activities Put Additional Burden on Doctors
October 5, 2009
- Price Gaps Remain Unchanged for Drugs Priced by Similar Efficacy Comparison Method
October 5, 2009
- Fixed-Dose Combination Drugs Should Be Priced at 10-30% of the Sum of Prices of Combined Drugs: Korosho
October 5, 2009
- Term of Office to Expire for 6 of 7 Chuikyo Members Representing Healthcare Providers
October 5, 2009
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…